About this Medicine article

Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT) by Reece, D.; Rodriguez, G.P.; Pantoja, M.; Paul, H.; Venner, C.P.; White, D.; Stakiw, J.; Sebag, M.; Comeau, T.; Song, K.; Roy, J.; Minuk, L.; Tay, J.; Kukreti, V.; Trudel, S.; Chen, C.; Tiedemann, R.; Prica, A. is a Medicine article available to read on EtoBox.

Author

Reece, D.; Rodriguez, G.P.; Pantoja, M.; Paul, H.; Venner, C.P.; White, D.; Stakiw, J.; Sebag, M.; Comeau, T.; Song, K.; Roy, J.; Minuk, L.; Tay, J.; Kukreti, V.; Trudel, S.; Chen, C.; Tiedemann, R.; Prica, A.

Publisher

Elsevier ; Cancer Media Group; Elsevier BV (ISSN 2152-2650)

Published

2015

Language

EN

Field

Medicine (Health Sciences)